Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anthem, Inc. stock logo
ANTX
Anthem
$4.50
-2.8%
$4.60
$1.00
$6.91
$162.07M-0.99422,831 shs591,722 shs
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
$20.95
-6.8%
$20.89
$89.95
$99.05
$607.24M0.9553,591 shs1.41 million shs
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
$14.00
+1.3%
$11.55
$2.35
$11.55
$416.53M-0.39486,688 shs1.25 million shs
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
$39.63
-7.5%
$30.18
$2.03
$14.36
$372.44M1.1150,104 shs290,583 shs
10 Stocks Set to Soar in 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anthem, Inc. stock logo
ANTX
Anthem
0.00%+1.81%+1.12%+51.52%+316.67%
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
-6.81%-2.60%+37.29%+17.10%+100.48%
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
+1.30%+8.53%+29.63%+66.47%+993.75%
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
-7.49%+12.14%+41.49%+94.46%+95.41%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anthem, Inc. stock logo
ANTX
Anthem
$4.50
-2.8%
$4.60
$1.00
$6.91
$162.07M-0.99422,831 shs591,722 shs
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
$20.95
-6.8%
$20.89
$89.95
$99.05
$607.24M0.9553,591 shs1.41 million shs
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
$14.00
+1.3%
$11.55
$2.35
$11.55
$416.53M-0.39486,688 shs1.25 million shs
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
$39.63
-7.5%
$30.18
$2.03
$14.36
$372.44M1.1150,104 shs290,583 shs
10 Stocks Set to Soar in 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anthem, Inc. stock logo
ANTX
Anthem
0.00%+1.81%+1.12%+51.52%+316.67%
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
-6.81%-2.60%+37.29%+17.10%+100.48%
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
+1.30%+8.53%+29.63%+66.47%+993.75%
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
-7.49%+12.14%+41.49%+94.46%+95.41%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Anthem, Inc. stock logo
ANTX
Anthem
2.00
Hold$9.00100.00% Upside
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
0.00
N/AN/AN/A
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
0.00
N/AN/AN/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ANTX, AVTE, ELYM, and NLTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/6/2026
Anthem, Inc. stock logo
ANTX
Anthem
Reiterated RatingSell (D-)
5/14/2026
Anthem, Inc. stock logo
ANTX
Anthem
UpgradeMarket PerformOutperform$9.00
(Data available from 7/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Anthem, Inc. stock logo
ANTX
Anthem
N/AN/AN/AN/A$1.94 per shareN/A
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
N/AN/AN/AN/A$3.96 per shareN/A
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
N/AN/AN/AN/A$3.90 per shareN/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/A$11.08 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Anthem, Inc. stock logo
ANTX
Anthem
-$35.17M-$1.10N/AN/AN/AN/A-52.35%-47.25%N/A
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%N/A
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
-$35.12M-$0.53N/AN/AN/AN/A-47.03%-45.97%N/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
-$57.56M-$3.11N/AN/AN/AN/A-37.22%-30.91%N/A

Latest ANTX, AVTE, ELYM, and NLTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/11/2026Q1 2026
Anthem, Inc. stock logo
ANTX
Anthem
-$0.23-$0.29-$0.06-$0.29N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Anthem, Inc. stock logo
ANTX
Anthem
N/AN/AN/AN/AN/A
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
N/AN/AN/AN/AN/A
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
N/AN/AN/AN/AN/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Anthem, Inc. stock logo
ANTX
Anthem
N/A
15.73
15.73
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
N/A
8.78
8.78
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
N/A
60.41
60.41
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/A
15.33
15.33

Institutional Ownership

CompanyInstitutional Ownership
Anthem, Inc. stock logo
ANTX
Anthem
90.47%
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
N/A
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
69.76%
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
52.37%

Insider Ownership

CompanyInsider Ownership
Anthem, Inc. stock logo
ANTX
Anthem
24.46%
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
24.90%
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
4.70%
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
1.58%
CompanyEmployeesShares OutstandingFree FloatOptionable
Anthem, Inc. stock logo
ANTX
Anthem
N/A36.02 million27.21 millionNot Optionable
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
2028.99 million21.69 millionOptionable
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
929.75 million28.35 millionNot Optionable
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
909.40 million9.25 millionNo Data

Recent News About These Companies

(NGNE) Proactive Strategies
Neurogene concludes merger deal with Neoleukin Therapeutics
Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split
Pre-market Movers: ORTX, CMBM, GROM, RSVR, FEMY…
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split
Neoleukin Therapeutics Recent Insider Activity

Media Sentiment Over Time

Anthem stock logo

Anthem NASDAQ:ANTX

$4.50 -0.13 (-2.81%)
Closing price 07/10/2026 04:00 PM Eastern
Extended Trading
$4.50 +0.00 (+0.11%)
As of 07/10/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through three segments: Commercial & Specialty Business, Government Business, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small group, individual, Medicaid, and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, such as consumer-driven health plans; and hospital only and limited benefit products. The company also provides a range of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs, and other administrative services. In addition, it offers an array of specialty and other insurance products and services, such as dental, vision, life and disability insurance benefits, radiology benefit management, and analytics-driven personal health care guidance; and Medicare administrative services. Further, the company provides services to the federal government in connection with the Federal Employee Program; and operates as a licensee of the Blue Cross and Blue Shield Association. As of December 31, 2017, it served 40.2 million medical members through its affiliated health plans. The company was formerly known as WellPoint, Inc. and changed its name to Anthem, Inc. in December 2014. Anthem, Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.

Aerovate Therapeutics stock logo

Aerovate Therapeutics NASDAQ:AVTE

$20.95 -1.53 (-6.81%)
As of 07/10/2026

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Eliem Therapeutics stock logo

Eliem Therapeutics NASDAQ:ELYM

$14.00 +0.18 (+1.30%)
As of 07/10/2026

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Neoleukin Therapeutics stock logo

Neoleukin Therapeutics NASDAQ:NLTX

$39.63 -3.21 (-7.49%)
As of 07/10/2026

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.